Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$11.04 -6.0%	$14.01	$7.05 ▼ $17.15	$289.80M	0.37	58,648 shs	98,440 shs
CMPS COMPASS Pathways	$4.30 +10.8%	$3.95	$2.25 ▼ $8.54	$402.32M	2.12	1.31 million shs	4.57 million shs
GOSS Gossamer Bio	$1.70 -0.6%	$1.27	$0.66 ▼ $1.90	$386.41M	1.86	1.47 million shs	3.18 million shs
XTNT Xtant Medical	$0.63 +1.4%	$0.66	$0.33 ▼ $0.80	$87.62M	-0.14	123,973 shs	42,766 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-5.96%	-13.62%	-26.10%	-19.71%	+13.81%
CMPS COMPASS Pathways	+10.82%	+17.17%	-10.42%	+37.38%	-42.36%
GOSS Gossamer Bio	-0.58%	+25.00%	+31.78%	+102.38%	+55.96%
XTNT Xtant Medical	+1.44%	-3.98%	+6.81%	+40.07%	-11.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTC Benitec Biopharma	1.9171 of 5 stars	3.6	1.0	0.0	3.4	0.8	0.0
CMPS COMPASS Pathways	2.0198 of 5 stars	3.4	1.0	0.0	3.0	0.8	0.6
GOSS Gossamer Bio	3.7744 of 5 stars	3.5	1.0	4.7	2.4	1.7	0.0
XTNT Xtant Medical	2.2782 of 5 stars	3.5	5.0	0.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	3.20	Buy	$23.83	115.88% Upside
CMPS COMPASS Pathways	2.86	Moderate Buy	$17.00	295.35% Upside
GOSS Gossamer Bio	3.00	Buy	$8.25	385.29% Upside
XTNT Xtant Medical	3.00	Buy	$1.50	138.51% Upside

Current Analyst Ratings Breakdown

Latest XTNT, BNTC, GOSS, and CMPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/23/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/23/2025	CMPS COMPASS Pathways	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ In-Line	$11.00 ➝ $6.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	$80K	3,622.50	N/A	N/A	$4.68 per share	2.36
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
GOSS Gossamer Bio	$114.70M	3.37	N/A	N/A	$0.13 per share	13.08
XTNT Xtant Medical	$117.27M	0.75	N/A	N/A	$0.31 per share	2.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
XTNT Xtant Medical	-$16.45M	-$0.13	N/A	∞	N/A	-9.81%	-27.01%	-12.49%	8/14/2025 (Estimated)

Latest XTNT, BNTC, GOSS, and CMPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	N/A	N/A	N/A	$4.12 million	N/A
8/7/2025	Q2 2025	CMPS COMPASS Pathways	-$0.41	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
XTNT Xtant Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	0.01	14.80	14.80
CMPS COMPASS Pathways	0.11	10.18	10.18
GOSS Gossamer Bio	6.70	5.71	5.71
XTNT Xtant Medical	0.51	2.34	1.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
CMPS COMPASS Pathways	46.19%
GOSS Gossamer Bio	81.23%
XTNT Xtant Medical	69.33%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	1.30%
CMPS COMPASS Pathways	3.93%
GOSS Gossamer Bio	6.70%
XTNT Xtant Medical	9.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
XTNT Xtant Medical	120	139.32 million	125.81 million	Not Optionable

XTNT, BNTC, GOSS, and CMPS Headlines

Recent News About These Companies

Xtant Medical (NYSEAMERICAN:XTNT) Stock Passes Above Two Hundred Day Moving Average - Time to Sell?

July 18 at 5:07 AM | marketbeat.com

Xtant Medical (NYSEAMERICAN:XTNT) Stock Price Passes Above Two Hundred Day Moving Average - Here's What Happened

July 10, 2025 | marketbeat.com

Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine

July 8, 2025 | prnewswire.com

Xtant Medical (NYSEAMERICAN:XTNT) Stock Crosses Above 200-Day Moving Average - Time to Sell?

July 2, 2025 | marketbeat.com

Xtant Medical (NYSEAMERICAN:XTNT) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened

June 24, 2025 | marketbeat.com

Xtant Medical Holdings Inc Share Price (XTNT.US)

June 4, 2025 | lse.co.uk

Xtant Medical Announces the Launch of OsteoFactor Pro™

May 28, 2025 | prnewswire.com

Xtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2025 Earnings Call Transcript

May 13, 2025 | msn.com

Xtant Medical Holdings, Inc.: Xtant Medical Reports First Quarter 2025 Financial Results

May 13, 2025 | finanznachrichten.de

Xtant Medical Holdings Inc (XTNT) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ...

May 13, 2025 | finance.yahoo.com

Xtant Medical outlines 8–11% revenue growth target for 2025 as company completes vertical integration and launches new products

May 13, 2025 | msn.com

Xtant Medical Holdings, Inc. (XTNT) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Xtant Medical Reports First Quarter 2025 Financial Results

May 12, 2025 | prnewswire.com

6XTNT : A Glimpse of Xtant Medical Hldgs&#...

May 9, 2025 | benzinga.com

Xtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025

May 6, 2025 | prnewswire.com

Why Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Up 6.27%

April 29, 2025 | aaii.comA

Xtant Medical Launches Trivium™ Advanced Bone Graft for Superior Performance

April 23, 2025 | prnewswire.com

Xtant Medical secures investor support, projects Q1 revenue growth

April 18, 2025 | uk.investing.com

Xtant Medical sees Q1 revenue $32.8M-$33.1M, two estimates $30.65M

April 17, 2025 | markets.businessinsider.com

Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%

April 16, 2025 | prnewswire.com

Why Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Down 14.76%

April 10, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTNT, BNTC, GOSS, and CMPS Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$11.04 -0.70 (-5.96%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$11.06 +0.02 (+0.14%)

As of 07/18/2025 07:22 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

COMPASS Pathways NASDAQ:CMPS

$4.30 +0.42 (+10.82%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$4.31 +0.01 (+0.23%)

As of 07/18/2025 07:46 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Gossamer Bio NASDAQ:GOSS

$1.70 -0.01 (-0.58%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.68 -0.02 (-1.47%)

As of 07/18/2025 06:33 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Xtant Medical NYSEAMERICAN:XTNT

$0.63 +0.01 (+1.44%)

As of 07/18/2025 04:10 PM Eastern

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time